May 2026
1. LUONG QT, O'Kelly J, Braunstein GD, Hershman JM, et al
   Editor's Note: Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo.
   Clin Cancer Res. 2026;32:1912.
   

   >> Share

   
   April 2026
2. KONG Z, Liu Y, Lin YS, Li Z, et al
   Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial.
   Clin Cancer Res. 2026 Apr 21:OF1-OF11. doi: 10.1158/1078-0432.CCR-25-3970.
   

   >> Share

   
   
3. LI S, Wu CC, Marczyk VR, Loberg MA, et al
   PRECISE: A prognostic thyrocyte-derived gene signature for papillary thyroid carcinoma.
   Clin Cancer Res. 2026 Apr 20. doi: 10.1158/1078-0432.CCR-25-4488.
   

   >> Share

   
   
4. SHI F, Chai W, Yang H, Cao W, et al
   AL2846, a novel multi-kinase inhibitor, for previously treated radioiodine-refractory differentiated thyroid cancer: Exploratory clinical results from the phase Ib study.
   Clin Cancer Res. 2026 Apr 9. doi: 10.1158/1078-0432.CCR-25-3945.
   

   >> Share

   
   February 2026
5. LI JZ, Ricarte Filho J, Isaza AR, Hinkle K, et al
   DNA Methylation-based Risk Stratification and Classification of Pediatric Thyroid Carcinoma.
   Clin Cancer Res. 2026 Feb 17. doi: 10.1158/1078-0432.CCR-25-2109.
   

   >> Share

   
   January 2026
6. CHIRRA M, Elliott A, Shaikh H, McGrath J, et al
   Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.
   Clin Cancer Res. 2026 Jan 16. doi: 10.1158/1078-0432.CCR-25-3932.
   

   >> Share

   
   
7. JIANG L, Li X, Ma T, Zeng P, et al
   Clinical Significance for risk stratification of papillary thyroid cancer by TUMORFISHER circulating tumor cells technique.
   Clin Cancer Res. 2026 Jan 16. doi: 10.1158/1078-0432.CCR-25-2694.
   

   >> Share

   
   September 2025
8. SEHGAL K
   Personalized Thyroidology: Molecular Rewiring of Thyroid Nodule Management.
   Clin Cancer Res. 2025 Sep 26. doi: 10.1158/1078-0432.CCR-25-2474.
   

   >> Share

   
   June 2025
9. DING M, Wu G, Zhang S, Xie R, et al
   Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population.
   Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0270.
   

   >> Share

   
   
10. HARRISON C, Blake AK, Su Y, Tang L, et al
    Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
    Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0631.
    

    >> Share

    
    March 2025
11. LEE J, Shin Y, Kwak J, Park HL, et al
    Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
    Clin Cancer Res. 2025 Mar 12. doi: 10.1158/1078-0432.CCR-24-3562.
    

    >> Share

    
    November 2024
12. LI Q, Zhang W, Liao T, Gao Y, et al
    An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
    Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
    

    >> Share

    
    June 2024
13. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
    Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
    

    >> Share

    
    May 2024
14. HEFT NEAL ME, Haring CT, Bellile E, Jaffe CC, et al
    Phase II Clinical Trial of Intravenous Levothyroxine to Mitigate Pharyngocutaneous Fistula in Euthyroid Patients Undergoing Salvage Laryngectomy.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-24-0782.
    

    >> Share

    
    
15. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    

    >> Share

    
    April 2024
16. READ ML, Brookes K, Zha L, Manivannan S, et al
    Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
    Clin Cancer Res. 2024;30:1352-1366.
    

    >> Share

    
    January 2024
17. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    

    >> Share

    
    December 2023
18. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    

    >> Share

    
    November 2023
19. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    

    >> Share

    
    October 2023
20. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    

    >> Share

    
    September 2023
21. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    

    >> Share

    
    August 2023
22. CHI Y, Zheng X, Zhang Y, Shi F, et al
    Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
    Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
    

    >> Share

    
    June 2023
23. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    

    >> Share

    
    
24. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
    

    >> Share

    
    May 2023
25. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 May 16:CCR-23-0278. doi: 10.1158/1078-0432.CCR-23-0278.
    

    >> Share

    
    
26. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    

    >> Share

    
    April 2023
27. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share